Provided by Tiger Trade Technology Pte. Ltd.

Altimmune, Inc.

6.18
+0.52009.19%
Post-market: 6.340.1600+2.59%19:59 EST
Volume:5.79M
Turnover:34.73M
Market Cap:644.84M
PE:-5.85
High:6.22
Open:5.64
Low:5.60
Close:5.66
52wk High:7.73
52wk Low:2.90
Shares:104.34M
Float Shares:104.00M
Volume Ratio:0.76
T/O Rate:5.57%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.0561
EPS(LYR):-1.3388
ROE:-52.61%
ROA:-30.87%
PB:3.47
PE(LYR):-4.62

Loading ...

Altimmune's drug for a type of liver disease shows benefits in mid-stage study

Reuters
·
Dec 19, 2025

Altimmune Shares Climb 6.9% Premarket After Positive Trial Data

THOMSON REUTERS
·
Dec 19, 2025

Altimmune Reports Positive 48-Week Phase 2b Results for Pemvidutide in MASH Trial

Reuters
·
Dec 19, 2025

Altimmune Inc - Pemvidutide 1.8 Mg Dose Achieves 7.5% Weight Loss

THOMSON REUTERS
·
Dec 19, 2025

Altimmune Announces That Pemvidutide Achieved Key Measures of Success at 48 Weeks in Impact Phase 2B Mash Trial

THOMSON REUTERS
·
Dec 19, 2025

FACTBOX-Weight-loss drug developers line up to tap lucrative market as competition heats up

Reuters
·
Dec 12, 2025

BUZZ-U.S. STOCKS ON THE MOVE-Ideaya Biosciences, Omnicom Group, Targa Resources

Reuters
·
Dec 02, 2025

Altimmune CEO Vipin Garg to Step Down

MT Newswires Live
·
Dec 01, 2025

BUZZ-Altimmune falls as CEO Vipin Garg to step down

Reuters
·
Dec 01, 2025

BRIEF-Altimmune Announces CEO Transition, Succession Plan

Reuters
·
Dec 01, 2025

Altimmune Inc - Vipin Garg to Step Down as CEO Effective Jan 1, 2026

THOMSON REUTERS
·
Dec 01, 2025

Altimmune Inc - Vipin Garg to Serve as Advisor Through June 30, 2026

THOMSON REUTERS
·
Dec 01, 2025

Altimmune Inc - Jerry Durso to Assume Role of CEO and Retain Chairman Position

THOMSON REUTERS
·
Dec 01, 2025

Press Release: Altimmune Announces CEO Transition and Succession Plan

Dow Jones
·
Dec 01, 2025

FACTBOX-Weight-loss drug developers line up to tap lucrative market as competition heats up

Reuters
·
Nov 25, 2025

Altimmune Inc Files For Mixed Shelf Of Up To $400 Million - SEC Filing

Reuters
·
Nov 20, 2025

Altimmune Amends Loan And Security Agreement With Hercules Capital - SEC Filing

Reuters
·
Nov 20, 2025

TG Therapeutics Makes 2025 Deloitte Technology Fast 500™ List of America’s Fastest-Growing Companies

GlobeNewswire
·
Nov 19, 2025

2025 Ergothioneine Brand Comprehensive Evaluation Research Report: In-depth Analysis of Seven Popular Brands Based on Ingredient Efficacy, Technological Barriers, and Market Landscape

Deep News
·
Nov 18, 2025

Altimmune Inc. Publishes Results of Phase 2b Trial of Pemvidutide in MASH

Reuters
·
Nov 11, 2025